Literature DB >> 2880624

Paf-acether-induced death in mice: involvement of arachidonate metabolites and beta-adrenoceptors.

M Criscuoli, A Subissi.   

Abstract

Intravenous Paf-acether (Paf, 15-80 micrograms kg-1) killed conscious Swiss mice in a dose-dependent manner, without causing platelet aggregation in the lung microvasculature, or pulmonary oedema. Propranolol (0.01-10 mg kg-1, i.p.) potentiated the effects of an LD20 of Paf dose-dependently, while the beta 1-adrenoceptor selective antagonist, metoprolol, was three orders of magnitude less potent in this respect. Salbutamol (1 mg kg-1, i.p.) provided complete protection against an LD80 of Paf. High doses of indomethacin, aspirin, benoxaprofen and FPL 55712 given i.p. failed to inhibit the effects of an LD80 of Paf, while BW 755C (50-100 mg kg-1) exerted a dose-dependent protection and benzydamine (50 mg kg-1) and nordihydroguaiaretic acid (200 mg kg-1) were partially active. Dexamethasone (1-5 mg kg-1, s.c.) exerted a dose-dependent protection, when administered at least 4 h before Paf. In mice anaesthetized with urethane, Paf (1-30 micrograms kg-1) produced hypotension which was not clearly dose-related. The effects of the highest dose were also tested on the resistance of the lungs to inflation and found to produce bronchoconstriction. It may be concluded that pharmacological manipulation of beta 2-adrenoceptors modulates Paf-induced death in mice, while arachidonate metabolites of the cyclo-oxygenase pathway and peptidoleukotrienes do not appear to be involved. However, lipoxygenase products, distinct from peptidoleukotrienes, may play a role in this phenomenon. It is suggested that bronchoconstriction, probably associated with cardiovascular effects, is a major determinant of the acute toxicity of Paf in mice.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2880624      PMCID: PMC1917294          DOI: 10.1111/j.1476-5381.1987.tb16841.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  On the mode of action and biochemical properties of anti-inflammatory drugs [proceedings].

Authors:  S A Saeed; P A Kendall; N M Butt; H O Collier
Journal:  Biochem Soc Trans       Date:  1979-08       Impact factor: 5.407

Review 2.  Arachidonic acid metabolites and lung beta-adrenoceptor desensitization.

Authors:  M P Abbracchio; L Daffonchio; C Omini
Journal:  Pharmacol Res Commun       Date:  1986-02

3.  Evidence for an adrenergic homeostatic bronchodilator reflex mechanism.

Authors:  M W McCulloch; C Proctor; M J Rand
Journal:  Eur J Pharmacol       Date:  1967-12       Impact factor: 4.432

4.  Hypotensive activity of PAF-acether in rats.

Authors:  C G Caillard; S Mondot; J L Zundel; L Julou
Journal:  Agents Actions       Date:  1982-12

5.  Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine.

Authors:  D H Namm; A S Tadepalli; J A High
Journal:  Thromb Res       Date:  1982-02-15       Impact factor: 3.944

6.  Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives.

Authors:  B B Vargaftig; J Lefort; M Chignard; J Benveniste
Journal:  Eur J Pharmacol       Date:  1980-07-25       Impact factor: 4.432

Review 7.  Background and present status of research on platelet-activating factor (PAF-acether).

Authors:  B B Vargaftig; M Chignard; J Benveniste; J Lefort; F Wal
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

8.  Agonist-promoted high affinity state of the beta-adrenergic receptor in human neutrophils: modulation by corticosteroids.

Authors:  A O Davies; R J Lefkowitz
Journal:  J Clin Endocrinol Metab       Date:  1981-10       Impact factor: 5.958

9.  Hypotensive and vasodilatory activity of (+/-) 1-o-octadecyl-2-acetyl glyceryl-3-phosphorylcholine in the normotensive rat.

Authors:  F M Lai; C A Shepherd; P Cervoni; A Wissner
Journal:  Life Sci       Date:  1983-03-07       Impact factor: 5.037

10.  Acetyl glyceryl ether phosphorylcholine. Intravascular alterations following intravenous infusion into the baboon.

Authors:  L M McManus; R N Pinckard; F A Fitzpatrick; R A O'Rourke; M H Crawford; D J Hanahan
Journal:  Lab Invest       Date:  1981-10       Impact factor: 5.662

View more
  7 in total

1.  Induction of platelet-activating factor in mice by intravenous administration of a neutral fraction of bakers' yeast mannan.

Authors:  T Mikami; K Fukushi; M Ishitani; K Ishitani; S Suzuki; M Suzuki
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.

Authors:  T Yamada; M Saito; T Mase; H Hara; H Nagaoka; K Murase; K Tomioka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Platelet-activating factor contributes to Bacillus anthracis lethal toxin-associated damage.

Authors:  Johanna Rivera; Rani S Sellers; Wangyong Zeng; Nico van Rooijen; Arturo Casadevall; David L Goldman
Journal:  J Biol Chem       Date:  2014-01-29       Impact factor: 5.157

4.  Catecholamines released from the adrenal medulla exert a compensatory, protective effect at beta 2-adrenoceptors against Paf-induced death in mice.

Authors:  M Criscuoli; A Subissi
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

Review 5.  Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists.

Authors:  H O Heuer
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

6.  Differential effect of a PAF antagonist CV-3988 on active and passive anaphylactic shock in various mouse strains.

Authors:  A Arimura; M Harada
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Effect of the hetrazepinoic platelet-activating factor antagonist Bepafant (WEB 2170) in models of active and passive anaphylaxis in mice and guinea pigs.

Authors:  H O Heuer
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.